Bile Duct Cancer News and Research

Latest Bile Duct Cancer News and Research

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

Opisthorchis viverrini is a parasitic flatworm (or liver fluke) endemic throughout Thailand, the Lao People’s Democratic Republic, Vietnam and Cambodia. Humans are infected with this parasite when they eat a fluke encysted in inadequately cooked/preserved freshwater fish.

21 Sep 2014

Scientists crack genetic code of liver fluke parasite

Singapore-An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis technique developed at A*STAR's Genome Institute of Singapore (GIS).

11 Sep 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

Scientists sequence genome of Asian liver fluke, a cancer-causing parasite

Scientists have sequenced the genome and characterised the genes of the Asian liver fluke, Opisthorchis viverrini. This parasite causes diseases that affect millions of people in Asia and is associated with a fatal bile duct cancer.

16 Jul 2014

New approach may help develop more effective immunotherapy for metastatic melanoma

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.

1 Jul 2014

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

18 Jun 2014

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.

26 Mar 2014

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Physicians at Mayo Clinic's Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies.

14 Feb 2014

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer.

4 Nov 2013

Surgical oncologist receives grant further explore tumor suppressor function of mutated gene

Darren Carpizo, MD, PhD, a surgical oncologist in the Liver Cancer and Bile Duct Cancer Care Program at the Cancer Institute of New Jersey, has been awarded a $200,000 grant from the Sidney Kimmel Foundation for Cancer Research to further explore the effects of a compound identified in his laboratory found to restore tumor suppressor function of a mutated gene in cancer cells.

11 Jun 2013

Urine tests could improve diagnosis of liver cancer

New data from two clinical trials presented today at the International Liver Congress- 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.

26 Apr 2013

GW researcher gets NCI grant to study behavior of parasitic worm in bile duct cancer

Paul Brindley, Ph.D., professor of microbiology, immunology, and tropical medicine at the George Washington University School of Medicine and Health Sciences, was the recipient of a $1.7 million grant from the National Cancer Institute to study the behavior of a parasitic worm, rampant in Southeast Asia, known to cause infections that contribute to liver cancer.

16 Nov 2012

Bile duct cancer chosen as next indication for PCI Biotech

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has chosen bileduct cancer as the next indication for the use of its PCI (photochemical internalisation) localised cancer therapy. In this indication PCI Biotech’s proprietary photosensitiser Amphinex® will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to start the clinical Proof of Concept study within end of 1H 2013.

21 Aug 2012

Activating NOTCH and AKT gene may trigger cholangiocarcinoma

A rare type of cancer thought to derive from cells in the bile ducts of the liver may actually develop when one type of liver cell morphs into a totally different type, a process scientists used to consider all but impossible. UCSF researchers triggered this kind of cellular transformation-and caused tumors to form in mice-by activating just two genes.

17 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

MRI scans determine whether chemotherapy is working long before tumors shrink

26 Jun 2012

Significant breakthrough in understanding the cause of bile duct cancer

A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.

15 May 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Bile Duct Cancer News and Research

Latest Bile Duct Cancer News and Research

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Sequencing the Asian liver fluke genome: an interview with Dr Neil Young

Scientists crack genetic code of liver fluke parasite

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Scientists sequence genome of Asian liver fluke, a cancer-causing parasite

New approach may help develop more effective immunotherapy for metastatic melanoma

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Concordia Healthcare acquires Pinnacle Biologics

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

Surgical oncologist receives grant further explore tumor suppressor function of mutated gene

Urine tests could improve diagnosis of liver cancer

GW researcher gets NCI grant to study behavior of parasitic worm in bile duct cancer

Bile duct cancer chosen as next indication for PCI Biotech

Activating NOTCH and AKT gene may trigger cholangiocarcinoma

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

MRI scans determine whether chemotherapy is working long before tumors shrink

Significant breakthrough in understanding the cause of bile duct cancer

Safe method for destroying cancer cells using death cap mushroom poison

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Bile Duct Cancer News and Research

Latest Bile Duct Cancer News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in